Do not receive this medication if you are pregnant. It could cause
harm to the unborn baby. Use an effective form of birth control, and tell your doctor if you
become pregnant during treatment.
Ibritumomab can lower the blood cells that help your body fight infections. This can
make it easier for you to bleed from an injury or get sick from being around others who are ill.
Contact your doctor immediately if you develop signs of infection.
Do not receive a "live" vaccine while you are being treated with ibritumomab, and
avoid coming into contact with anyone who has recently received a live vaccine. There is a
chance that the virus could be passed on to you.
Some people receiving ibritumomab have developed "secondary" bone marrow or blood
cell cancers such as leukemia. Talk with your doctor about your individual risk while receiving
this medication.
What is ibritumomab?
Ibritumomab is a protein that targets white blood cells in the body. When ibritumomab is
attached to a radioactive chemical, the radiation is delivered directly to the tumor (lymphoma).
Ibritumomab is used in combination with other medicines to treat non-Hodgkin's
lymphoma.
Ibritumomab may also be used for purposes other than those listed in this medication
guide.
What should I discuss with my healthcare provider before receiving ibritumomab?
You should not receive this medication if you are allergic to ibritumomab, or to
radioactive chemicals or mouse proteins.
Before you receive ibritumomab, tell your doctor if you are allergic to any drugs, or if you
have:
If you have any of these conditions, you may need a dose adjustment
or special tests to safely receive ibritumomab.
FDA pregnancy category D. This medication can cause harm to an unborn baby. Do not receive ibritumomab if you are pregnant. Tell your doctor if you
become pregnant during treatment. Use an effective form of birth control while you are
receiving this medication.
It is not known whether ibritumomab passes into breast milk or if it could harm a
nursing baby. Do not receive ibritumomab without telling your doctor if you are breast-feeding a
baby.
Ibritumomab is made from human plasma (part of the blood) and may contain viruses and
other infectious agents that can cause disease. Although donated human plasma is screened,
tested, and treated to reduce the risk of it containing anything that could cause disease, there is
still a small possibility it could transmit disease. Talk with your doctor about the risks and
benefits of using this medication.
Some people receiving ibritumomab have developed "secondary" bone marrow or blood
cell cancers such as leukemia. Talk with your doctor about your individual risk while receiving
this medication.
Print
Email
FDA Alerts
Drug Info Tools
Medicare's drug plans are subsidized by the US federal government and offered through insurers.
